Last reviewed · How we verify

Aurigene Discovery Technologies Limited — Portfolio Competitive Intelligence Brief

Aurigene Discovery Technologies Limited pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Acerta Pharma BV · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
  5. Eli Lilly and Company · 1 shared drug class
  6. Fuji Yakuhin Co., Ltd. · 1 shared drug class
  7. Genzyme, a Sanofi Company · 1 shared drug class
  8. GlaxoSmithKline · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aurigene Discovery Technologies Limited:

Cite this brief

Drug Landscape (2026). Aurigene Discovery Technologies Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aurigene-discovery-technologies-limited. Accessed 2026-05-16.

Related